What can we learn from cancer of unknown primary in canine oncology?

Aline Khazzaka a, Elie Rassy b,⇑, Nicholas Pavlidis c

a Surgical Research Laboratory, Faculty of Medicine, Saint Joseph University, Lebanon
b Department of Medical Oncology, Faculty of Medicine, Saint Joseph University, Lebanon
c Professor Emeritus, University of Ioannina, Ioannina, Greece

Abstract
Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors that lack an identifiable primary site despite an extensive diagnostic work-up. It is a well-recognized entity that is characterized by early dissemination, aggressive clinical course, unpredictable metastatic pattern, intrinsic treatment resistance, and a dismal prognosis. Despite the molecular diagnostic workup and personalized therapy, the expected improvements in the diagnosis and treatment of CUP have not been achieved. Comparative oncology has a promising role in the exchange of knowledge and practices between humans and canines. Therefore, we intended to review the literature reporting on CUP in dogs in order to identify some interesting parallels and unique results that could be transposed to in-human research.

Introduction
Cancer of unknown primary (CUP) represents a heterogeneous group of metastatic tumors that lacks a primary culprit after a standardized diagnostic workup [1]. The diagnostic advances in rigorous immunohistochemistry stainings and sophisticated imaging studies have decreased the prevalence of patients with CUP from 3 to 5% in the early 1990s to 1–2% currently [2]. The process that gives rise to CUP, characterized by early metastatic spread, regression of the primary site, and aggressive course of the disease, has not been fully elucidated [3–5]. Three hypotheses have been suggested to understand the mechanisms underlying the
carcinogenesis of CUP. The first hypothesis considers that CUP undergoes a type 2 progression thus malignant lesion formation without prior nascent primary tumor and not a type 1 progression from a premalignant to a malignant lesion. The second hypothesis is that CUP arises early in the development of a malignancy following a parallel progression model and does not develop according to a stepwise progression according to a linear progression model. Last, CUP at be attributed to the migration of deregulated, prema-
lignant, or cancerous stem cells away from their natural tissues and to form tumors in other locations [5]

The correct diagnosis of CUP strongly relies on the clinical presentation and optimal diagnostic workup [3,6,7]. The clinical reality describes a subset of cancer patients without an identifiable primary and unique natural history characterized by a short history of symp-toms and signs, early dissemination, aggressive behavior, and unpredictable metastatic patterns [4]. Traditionally, CUP patients are categorized into two prognostic subsets according to their clini-
copathologic criteria [2,4]. A minority of patients with CUP (15–20%) presents a constellation of criteria that is highly suggestive of a specific site of origin, is treated accordingly and has a good prognosis whereas the majority (80–85%) is treated with empirical chemotherapy and usually presents a dismal prognosis [1,4]. Despite the molecular diagnostic workup and personalized therapy, the expected improvements in the diagnosis and treatment of CUP have not been achieved [3,5,8,9]. Comparative oncology has a promising role in the exchange of knowledge and practices between humans and animals. Canine models have a particular advantage over other animal models [10,11]. They have many genes similarities with humans, five to seven-fold accelerated aging compared to humans, respond to treatments similarly as humans do, and health care levels second only to humans [11]. This paper aims to review the clinicopathologic presentations, treatment trends, and prognosis of veterinary cases with CUP in order to identify some interesting parallels and unique results that could be transposed to in-human research.

Materials and methods

The Medline database (via PubMed) and Google Scholar were searched by using the relevant keywords for a combined search using the following phrases (cancer of unknown primary) OR (CUP) AND (dogs), (cancer of unknown primary) OR (CUP) AND (companion animals), (cancer of unknown primary) OR (CUP) AND (domestic animals). The resulting publications identified with this search strategy on July 19th, 2019 were examined by two reviewers (AK and ER) for their title and abstract. No language or time limitations were applied. The reference sections of the publi-
cations of interest were examined to identify other potentially rel-
levant publications. Eligible publications/cases were selected if the veterinary patient presents a histological confirmed metastatic tumor without an identified primary after an adequate work-up at the time of diagnosis. The following details were retrieved: clinical presentation, physical examination, blood analysis, histopathology, imaging, treatment, and outcome.

Results

Clinical presentation

Our review of the literature identified 33 dogs diagnosed with CUP (Table 1). The median age at diagnosis in CUP is 10 years (range 4–15 years) with a female: male ratio of 1.3 [12–15]. The majority has symptomatic tumors including which manifested in lameness (n = 11) [12,13], depression/weakness (n = 10) [12,13], pain (n = 9) [12–15], dyspnea (n = 8) [12,14], lethargy (n = 4) [12–14], anorexia (n = 3) [13], weight loss (n = 2) [13], stiff gait (n = 2) [13], tenesmus (n = 1) [13], polyuria/polydipsia (n = 1) [12], and progressive tetraparesis (n = 1) [15].

Diagnostic work-up

The minimal basic work-up reported include physical examination (including head and neck, rectal, pelvic and breast examination), basic blood and biochemical analyses, as well as chest and abdominal radiography (Table 1). The diagnosis of CUP was confirmed by pathologic evaluation which can be categorized into a majority of undifferentiated carcinomas followed by sarcomas, squamous cell carcinomas, and mast cell tumor. Patients had commonly two metastatic sites or more at diagnosis (Table 1). The immunohistochemistry algorithm and staining were not always detailed. Undifferentiated carcinomas (n = 9) were pan-cytokeratin positive and vimentin negative (n = 6); pan-cytokeratin negative, vimentin positive and CD18 negative (n = 3), and pan-cytokeratin positive, vimentin negative and TTF1 negative (n = 1) [12]. The delay between symptomatic manifesta-
tion and diagnosis was approximately 2–3 weeks [12,13].

Treatment and prognosis

The majority of patients with CUP did not receive anti-cancerous therapy with 4 being euthanized shortly after diagnosis. Treatments vary between systemic or metronomic chemotherapy, surgery, palliative radiation therapy with or without surgery. Nine reported cases were treated with palliative care (n = 3; one case with pericardial effusion treated cephalaxin, prednisone, colchicine plus microprostol before being euthanized), chemotherapy (n = 5 among which 2 were treated with metronomic regimens), targeted therapy (one case treated with toceranib), radiotherapy (n = 1) and surgery (n = 2). The prognosis was dismal as the median survival was limited to 4 weeks (range 0.4–72 weeks) (Table 1).

Discussion

Cancer of unknown primary is often neglected in veterinary oncology which limits the understanding of this entity overall and in animals particularly [12]. In human oncology, the diagnosis of CUP is not straightforward and is often a diagnosis of exclusion with primaries being identified in 75% of cases at autopsy [16]. The pub-
lished literature in veterinary oncology focusing on CUP is very sparse. The majority of the reported veterinary cases with CUP are dogs whereas few cases included cattles and mules [18]. This review identified 33 dogs with a histologically confirmed CUP diagnosis. The minimal basic workup included physical examination, basic blood, and biochemical analyses, chest and abdominal radiography. Interestingly, the reported cases did not report any evaluation of tumor markers or the use of sophisticated imaging. The most com-
monly identified histologies include undifferentiated carcinomas followed by squamous cell carcinomas, sarcomas, and melanomas. Unfortunately, the immunohistochemical patterns cannot be comprehensively analyzed as most cases did not detail the stains that were performed (Table 1). Moreover, a limited panel of immunohis-
tochemical stainings was commonly used mainly because of financial concerns and the lack of site-specific markers [12].

Among humans, the failure to identify the culprit tumors often delays treatment decisions. Oncologists and patients do not fare well with the diagnosis which puts into question the accuracy of the diagnostic approach. Subsequently, further testing is performed whereas quick treatment decisions are required instead of spending the remaining lifetime, which lies in the range of one year, performing diagnostic tests [17]. The median survival of cani-
| Study | Patient/gender/age | Clinical presentation | Diagnostic workup | Findings | Histology | Treatment | Outcome |
|-------|--------------------|-----------------------|-------------------|----------|-----------|-----------|---------|
| Cooley and Waters 1998 [13] | Golden retriever/M/11 years | Left forelimb lameness; stiff gait; lethargy; anorexia | Thoracic and abdominal radiography | Thoracic and abdominal Radiography | Carcinoma, NS | NR | Median survival 4 weeks |
| | Labrador retriever/M/8 years | | | | | | |
| | Airedale Terrier/F spayed/11 years | Left forelimb lameness; weight loss | Thoracic and abdominal radiography | Abdominal US; cardiac US | Carcinoma, NS | NR | |
| | Mixed breed/F spayed/10 years | Left hindlimb lameness; weight loss | Thoracic and abdominal radiography | Abdominal US | Carcinoma, NS | NR | |
| | Beagle/F spayed/6 years | Left hindlimb lameness; weight loss | Thoracic and abdominal radiography | Abdominal US | Carcinoma, NS | NR | |
| | Mixed breed/F/12 years | Masson rib; painful when rising | Thoracic and abdominal radiography | Abdominal Radiography | Carcinoma, NS | NR | |
| | Australian shepherd/F/9 years | Progressive posterior paresis; depression; anorexia | Thoracic and abdominal radiography | Abdominal US | Carcinoma, NS | NR | |
| | Golden retriever/F/11 years | Progressive posterior paresis; depression | Thoracic radiography | Carcinoma, NS | NR | |
| | Mixed breed/M/9 years | Listless progressive hindlimb weakness | Thoracic and abdominal radiography | Abdominal US | Carcinoma, NS | NR | |
| | Mixed breed/ M/4 years | Painful ambulation; listlessness; anorexia | Thoracic and abdominal radiography | Abdominal US | Carcinoma, NS | NR | |
| | Miniature poodle/F/13 years | Cervical pain; stiff gait; left forelimb nonspecific pain | Thoracic radiography | Cardiac tamponade and weakness; elevated liver enzymes; abdominal distension and painful abdomen | Carcinoma, NS | NR | |
| | | | | | | | |
| Kirsch et al., 2000 [14] | Siberian husky/F spayed/6.5 years | Lethargy; tachypnea; painful abdomen | Physical examination; blood tests; Cardiac ultrasound; IHC | Cardiac tamponade and weakness; elevated liver enzymes; abdominal distension and painful abdomen | Emboli of metastatic cells carcinoma in the epicardium | Pericardiocentesis; pericardectomy after pericardial effusion recurrence; after the persistence of thoracic effusion: | |
| | | | | | | | |
| Rossi et al., 2015 [12] | Cocker/M/8 years | Symptomatic | Physical examination; blood tests; IHC; light microscopy; total body-CT | Multiple nodules in the spleen | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-); mast cell tumor | Chemotherapy | Died after 7 months |
| | Labrador retriever/F spayed/10 years | Asymptomatic | | Multiple nodules in the axillary lymph nodes | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-); mast cell tumor | Surgery, toceranib | Died after 8 months |
| | Beagle/F spayed/9 years | | | | | | |
| | Corso dog/F spayed/7 years | Symptomatic | | | | | |
| | Mixed breed/F/12 years | Symptomatic | | | | | |

(continued on next page)
| Study | Patient/gender/age | Clinical presentation | Diagnostic workup | Findings | Histology | Treatment | Outcome |
|-------|-------------------|----------------------|-------------------|----------|-----------|-----------|---------|
|       |                   | Symptomatic          |                   | Multiple nodules in the heart, muscles, subcutis and kidneys | Fibrosarcoma | radiation therapy | Euthanasia at diagnosis |
|       | Beagle/F spayed/11 years | Symptomatic          |                   | Multiple nodules in the lungs, liver, adrenal gland, spleen, omentum, ileum, vertebral body T3 | Fibrosarcoma | No treatment | Euthanasia at diagnosis |
|       | German Shepherd/M/8 years | Symptomatic          |                   | Multiple nodules in the pleurae | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-, TTF1-) | No treatment | Euthanasia at diagnosis |
|       | German Shepherd/M/8 years | Symptomatic          |                   | Multiple nodules in the pericardium | Squamous cell carcinoma | No treatment | Died after 5 days |
|       | West Highland White Terrier/F spayed/13 years | Symptomatic          |                   | Multiple nodules in the peripheral, intrathoracic and abdominal lymph nodes (axillary, sternal, mediastinal, Mesenteric, medial iliac, lombo-aortic), adrenal glands, liver, pancreas, lungs and muscles. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-) | Palliative care | Died after 3 months |
|       | Rhodesian ridgeback/F spayed/10 years | Asymptomatic          |                   | Multiple nodules in the subcutaneous tissue and lungs. | Undifferentiated carcinoma (pan-cytokeratin-, CD18-, vimentin + ) | Metronomic chemotherapy | Died after 2.5 months |
|       | Corso dog/M/10 years | Symptomatic          |                   | Multiple nodules in the vertebral body (T2, L1, L2, L5), spleen and liver. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-) | No treatment | Died after 2 weeks |
|       | Siberian husky/M/8 years | Symptomatic          |                   | Multiple nodules in the lungs, spleen and liver | Hemangiosarcoma (vimentin+, Factor VIII + ) | No treatment | Died after 1.5 months |
|       | Labrador retriever/M/15 years | Symptomatic          |                   | Multiple nodules in vertebrae body (L2, L5), spleen and liver | Hemangiosarcoma (vimentin+, Factor VIII + ) | No treatment | Died after 5 days |
|       | Boxer/M/11 years | Symptomatic          |                   | Multiple nodules in the base of the heart, liver and retroperitoneal space. | Hemangiosarcoma (vimentin+, Factor VIII + ) | No treatment | Died after 4 days |
|       | Mixed breed/M/14 years | Symptomatic          |                   | Multiple nodules in the lungs. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-, TTF1-) | Metronomic chemotherapy | Died after 10 days |
|       | American Staffordshire terrier/M/10 years | Symptomatic          |                   | Multiple nodules in the lungs. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-, TTF1-) | Metronomic chemotherapy | Died after 1 month |
|       | Beauceron/M/10 years | Symptomatic          |                   | Multiple nodules in the lungs and spleen. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-, TTF1-) | No treatment | Died after 3 days |
|       | Weimaraner/F/11 years | Symptomatic          |                   | Multiple nodules in the lungs and tracheobronchial lymph nodes. | Undifferentiated carcinoma (pan-cytokeratin+, vimentin-, TTF1-) | No treatment | Died after 7 days |
|       | Miyazaki et al., 2016 [15] | Cervical pain and progressive tetraparesis | Physical examination; Blood tests; MRI; Cervical Radiography Abdominal US CT-Scan; IHC | Mass in the dorsal atlantoaxial region | Squamous cell carcinoma | No treatment | Death 32 days post-palliative surgery. |
|       | Chihuahua/F/12 years | Cough; tachypnea; muffled heart sounds; decreased appetite and depression. | Physical examination; blood tests; thoracic radiography; electrocardiography; pericardial effusion analysis; multi-detector computed tomography and IHC | Pericardial effusion; no mass lesions was found at the heart base, aorta and right atrium; hemorrhagic cytology of the pericardial effusion. Metastatic carcinoma involving epicardium, sternal lymph nodes and multiple lung nodes. | Carcinoma pan-cytokeratin+, vimentin- | Conservative treatment with steroids and diuretics | Died after 457 days |

F: female; IHC: immunohistochemistry; M: male; NR: not reported; NS: not specified.
nes with CUP is approximately 4 weeks which limits an extensive diagnostic testing. The prevalence of euthanasia at diagnosis and the non-uniformity of treatment approaches limit solid conclusions and extrapolations to CUP in humans (Table 1).

Comparative oncology on this topic is mainly limited by the relatively low numbers of reported cases which can be attributed to the rare occurrence of CUP in canines or the underreporting publication bias. The reported literature shows that dogs are commonly quickly euthanized at diagnosis which is a further disadvantage when trying to support research on the topic. A descriptive database and clinical trial registry would overcome these limitations and would help dog owners and veterinarians to start trials for pets suffering from CUP while taking into consideration animal welfare. Moreover, as CUP in canines mimics the human pathological conditions, genetic studies similarly to those reported by the Comparative Oncology and Genomics Consortium (CCOGC; www.ccogc.net) Inc., should provide quality data that address the gaps in understanding the CUP carcinogenesis and preclinical studies such as those conducted by the Comparative Oncology Program (COP; https://cancer.gov/comparative-oncology-program) may help in identifying the promising drugs before entering the traditional phase I in-human trials.

Conclusion

As comparative oncology helps in studying disease patterns, inheritance, and genetic history, the purpose of this paper was to evaluate whether relevant lessons can be learned from CUP research in animals, particularly canines, and the possibility of transferring this research to in-human studies. The review of the published data on veterinary cases identified many similarities between humans and animals with CUP in regards to the diagnostic approach and prognosis. The standard workup for veterinary patients with CUP includes a physical examination, basic blood tests, pathology and immunohistochemical analysis, chest and abdominal imaging. The prognosis is dismal and the median survival is four weeks with several cases being euthanized at diagnosis. In view of the similarities between the characteristics of CUP between humans and canines, the value of comparative oncology can be recognized in the field of CUP research.

Compliance with Ethics Requirements

This article does not contain any studies with human or animal subjects.

Declaration of Competing Interest

None.

Funding

None.

Acknowledgment

None.

References

[1] Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Paoloni MC. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(Suppl 5):v133–8. https://doi.org/10.1093/annonc/mdv305.

[2] Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 2019;61:139–41. https://doi.org/10.1016/j.canep.2019.06.006.

[3] Rassy E, Assi T, Pavlidis N. Exploring the biological hallmarks of cancer of unknown primary: where do we stand today?. Br J Cancer 2020;1:9. https://doi.org/10.1038/s41416-019-0723-4.

[4] Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379:1428–35. https://doi.org/10.1016/S0140-6736(12)61178-3.

[5] Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol 2020;1:1–14. https://doi.org/10.1038/s41571-020-0359-1.

[6] Bochler T, Endris V, Leischendorf S, Reiling A, Neumann O, Volckmar A, et al. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Int J Cancer n.d. https://doi.org/10.1002/ijc.32316.

[7] Rassy E, Kattan J, Pavlidis N. Familial cancer of unknown primary. Int J Clin Oncol 2019. https://doi.org/10.1007/s10147-019-01491-1.

[8] El Rassy E, Pavlidis N. The current evidence for a biomarker-based approach in cancer of unknown primary. Cancer Treat Rev 2018;67:21–8. https://doi.org/10.1016/j.ctrv.2018.04.011.

[9] Rassy E, Bakouny Z, Choueiri TK, Van Allen EM, Fizazi K, Greco FA, et al. The role of site-specific therapy for cancers of unknown primary: A meta-analysis. Eur J Cancer 2020;127:118–22. https://doi.org/10.1016/j.ejca.2020.02.009.

[10] Paoloni MC, Khanna C. Comparative Oncology Today. Vet Clin North Am Small Anim Pract 2007;37:1023–v. https://doi.org/10.1016/j.cvsm.2007.08.003.

[11] Sultan F, Ganaie BA. Comparative oncology: Integrating human and veterinary medicine. Open Vet J 2018;8:25–34. https://doi.org/10.4314/ojv.s.8-1.5.

[12] Rossi F, Arnesu L, Vignoli M, Buracco P, Bettini G, Ferro S, et al. Metastatic cancer of unknown primary in 21 dogs. Vet Comp Oncol 2015;13:11–9. https://doi.org/10.1111/vco.12031.

[13] Cooley DM, Waters DJ. Skeletal metastasis as the initial clinical manifestation of metastatic carcinoma in 19 dogs. J Vet Intern Med 1998;12:288–93. https://doi.org/10.1111/j.1939-1676.1998.tb21244.x.

[14] Kirsch JA, Dhupa S, Cornell KK. Pericardial effusion associated with metastatic disease from an unknown primary tumor in a dog. J Am Anim Hosp Assoc 2000;36:121–4. https://doi.org/10.1539/1547-3317-36.2.121.

[15] Miyazaki Y, Atsuki T, Nishimura M, Iwata M, Kagawa Y. Squamous cell carcinoma causing dorsal atlantoaxial spinal cord compression in a dog. Can Vet J 2016;57:1049–52.

[16] Pentheroudakis G, Biasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology?. Oncologist 2007;12:418–25. https://doi.org/10.1634/theoncologist.12-4-418.

[17] Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007;46:592–601. https://doi.org/10.1080/02841070701243095.

[18] Brakel KA, VanHoy G, Hinds A, Breitbach J, Premanandan C, Guiberteau J, Peritoneal and scrotal carcinomas of unknown origin in two bovine calves. J Vet Diagn Invest 2018;30:609–13. https://doi.org/10.1177/1040638718765617.

[19] Kang MH, Sur JH, Park HM. Pericardial effusion in a dog concurrent with carcinoma of unknown primary origin. Iran J Vet Res 2019;20:225–8.
Nicholas Pavlidis is a Professor Emeritus of Medical Oncology at the University of Ioannina, Greece. Cancer of unknown primary is one of his research fields. He was the Chairman of the ESMO Guidelines Committee (2006–2011) and Chairman of the ASCO/ESMO Core Curriculum of Medical Oncology (2011-2014). Currently, he is the Dean of the College of the European School of Oncology and the Coordinator of Educational Activities at the European School of Oncology. He is a member of the Scientific Committee of the European School of Oncology and Chairman of various educational activities.